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Abstract:  Several  new  pyrazolopyrimidine  compounds  were  achieved  from  aminocyanopyarazole  1.                         
The starting material 1 was initially coupled with orthoester at refluxed with various primary amines, ammonia, 
hydrazines and hydroxylamine to furnish a series of pyrazolo[3,4-d]pyrimidines.  The reaction of imidate 2a-b 
with hydrazide derivatives led to the formation of pyrazolo[3,4-d][1,2,4]triazolo[4,3-c]pyrimidines.  Some of the 
synthesized  compounds 3a  and  4c were  evaluated  for  their  anti-inflammatory,  antipyretic  and  nociceptive 
activities.  We start by studing the toxicity of these two molecules by measuring the corresponding DL50.  The 
DL50 of 3a and 4c are estimated to 1333.2mg / kg and 1593.5mg / kg respectively.  Pharmacological evaluation 
showed  that  compounds  3a  and  4c   at  doses  (5.5-22.2  mg  /  Kg,  i.p)  exhibited  anti-inflammatory  activities 
compared to Ibuprofen (150 mg / Kg, i.p), used as a refer ence drug.  Further, our study showed that the injection 
of derived pyrazolopyrimidines on hyperthermic animal leads to a decrease in temperature after 1 hours of 
treatment compared to paracetamol used as reference. In addition, the injection of derived pyrazolopyrimidines 
at different doses contains a potent nociceptive activity.  This effect is dose-dependent compared to aspirin. 
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rearrangement. 
 
Introduction 
 
In recent years, pyrazole and pyrimidine derivatives attracted organic chemists due to their 
widespread potential biological and chemotherapeutic activities.  Pyrazolopyrimidines and 
related  heterocyles  are  found  to  possess  wide  applications  in  the  field  of  medicine  and 
agriculture.  They are biologically active isomeric purine analogues and have useful properties 
as antimetabolites in purine biochemical reactions
1-3.  They  exhibit wide pharmacological 
activities like tuberculostatic
4 antimicrobial
5, neuroleptic
6, antitumor
7, antihypertensive
8 and 
antileishmanial activities
9. 
Stimulated by the successful application of pyrazolo[3,4-d]pyrimidines, our objective was 
to synthesize a new class of pyrazolo[3,4-d]pyrimidine analogues 3a-c, 4a-b by introducing 
various  groups  at  the  pyrazolopyrimidine  ring  and  to  evaluate  its  anti-inflammatory, 
nociceptive and antipyretic activities. 
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Results and Discussion 
 
Chemistry 
Several works mentioned the synthesis of 5-amino-4-cyano pyrazoles
10-12.  These products 
were  prepared  via  a  standard  addition  of  hydrazine  derivatives  to  ethoxymethylene 
compounds.  To generalize the synthesis of 5-amino-4-cyano-1-substituted pyrazoles 1, we 
have prepared a variety of unsaturated ethoxymethylene compounds in good yields and the 
corresponding pyrazoles.  The 5-amino pyrazole-4-carbonitrile 1a-e react with orthoester to 
give the corresponding imidate derivatives 2a-e (Scheme 1), these later are used as precursors 
for the synthesis of various pyrazolo[3,4-d]pyrimidines. 
 
Scheme 1.  Synthesis of 4-cyano-1-phenyl-1H-pyrazoloimidate 2 
 
Table 1.  Synthesis of imidates derivatives  
Entry  R1  R2  Yield % 
2a  H  H  70 
2b  H  Me  62 
2c  Me  H  70 
2d  Me  Me  40 
2e  Me  Et  25 
 
Reaction of imidates 2 with some primary aromatic amines, ammonia, hydrazines and 
hydroxylamine  gave  new  pyrazolo[3,4-d]pyrimidine  derivatives  of  significant  biological 
interest  since  such  compounds  are  substituted  analogues  of  the  well-known  drug  
Allopurinol
13. 
The imidate 2 reacted at their both electrophilic sites with aromatic amines to yield the 
pyrazolopyrimidines type 3a-f in two steps. Firstly, the condensation of 2 with amines in 
toluene in the presence of a catalytic amount of acetic acid led to the intermediate 3’ by the 
nucleophilic attack of the NH2 motif on imidic carbon. In the second step, the non isolable 
amidine  3’  was  transformed  into  the  novel  pyrazolopyrimidines  3a-f  via  Dimroth 
rearrangement.  The  isomerization  of  3’  into  the  thermodynamically  more  stable 
pyrazolopyrimidines derivative 3a-f (Scheme 2) seems to occur through acid / base-catalysed 
in tandem of ring opening followed by ring closure.  This rearrangement is consistent with 
those reported in some earlier reports
14,15. Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  866 
 
 
Scheme 2.  Synthetic route of compounds 3-6. Reagents and conditions:                                    
(i) R3-NH2,AcOH, Toluene. (ii) R3-NH-NH2, AcOH, Toluene.                                                 
(iii) NH3, EtOH. (iv) NH2OH/HCl, EtOH, NEt3. 
Table 2.  Synthesis of pyrazolo[3,4-d]pyrimidines derivatives 
Entry  R1  R2  R3 
3a  CH3  H  Ph 
3b  CH3  CH3  Ph 
3c  CH3  H  CH2-Ph 
3d  CH3  CH3  CH2-Ph 
3e  CH3  H  Naphtyl 
3f  CH3  CH3  Naphtyl 
4a  CH3  H  H 
4b  CH3  CH3  H 
4c  CH3  H  Ts 
4d  CH3  CH3  Ts 
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Therefore, to confirm the structure of compounds 3, an X-ray crystallographic study was 
carried out of compound 3d obtained by condensation of 2d with aniline (Figure 1).  Crystals 
were obtained by slow evaporation from ethanol / DMSO-d6 solution. 
 
Figure 1.  X-ray crystal analysis of compound 3d 
 
It  seemed  of  interest  to  study  the  analogous  reactions  of  imidate  derivatives  2  with 
hydrazides.  Treatment of imidates 2 with an equivalent of hydrazides in toluene for 24 h gave 
pyrazolo[3,4-d][1,2,4]triazolo[4,3-c]pyrimidines 8. 
Successive two nucleophilic additions of NH2 group of hydrazide to the imidic carbon and 
to  the cyano  was observed to  yield the intermediates amidopyrazolopyrimidines 7’.  The 
formation  of  7’  was  followed  by  an  intracyclisation  via  elimination  of  water  to  give 
pyrazolotriazolopyrimidines 8.  The IR spectrum revealed the absence of the characteristic 
absorption bands corresponding to cyano, amino and CO groups. 
 
Scheme 3.  Synthesis of pyrazolo[3,4-d][1,2,4]triazolo[4,3-c]pyrimidines 
 
Table 3.  Synthesis of pyrazolo[3,4-d][1,2,4]triazolo[4,3-c]pyrimidines 
compounds  R1  R2  R4  Yield (%)  mp°C 
8a  CH3  H  Ph  79  232 
8b  CH3  CH3  Ph  42  241 
8c  CH3  H  CH3  48  201 
8d  CH3  CH3  CH3  52  130 
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Biological evaluation 
 
Determination of LD50 of compounds 3a and 4c in adult mice  
The  acute  toxicity  of  the  two  test  compounds  (3-methyl-N,1-diphenyl-1H-pyrazolo                   
[3,4-d]pyrimidin-4-amine  3a  and  4-methyl-N-(3-methyl-1-phenyl-1H-pyrazolo[3,4-d] 
pyrimidine-4-yl)benzenesulfonohydraine 4c) in mice indicated their good safety profiles and 
their  median  lethal  intraperitoneal  doses  (LD50)  values  were  found  to  be  1332.2  and                     
1593.5 mg / kg b.w., respectively. 
 
Evaluation of Antipyretic activity 
The  effect  of  tested  compounds  (3a  and  4c)  on  normal  body  temperature  in  rats  is 
presented in Table 4.  The results showed that 3a and 4c at dose of 22.2 mg / kg (1/50 LD50) 
caused  significant  lowering  of  the  body  temperature  up  to  4  hours.    The  normal  mean 
temperature 38.37°C at 0 hour was reduced to 36.67 °C after 4 hours for the compound 3a. 
Further, Lowering of body temperature was noticed for the compound 4c, in fact the mean 
temperature 38.97°C at 0 hour was reduced to 36.67°C within a 4 hour period.  Time of peak 
effect  was  obtained  from  2  to  4  h  after  oral  administration  of  test  drugs.    Paracetamol                 
(150mg / kg b.w.) also suppressed hyperthermia induced by yeast during all the observation 
times when compared with control values. 
 
Table 4.  Evaluation of Antipyretic activity 
  dose  t0  30min  1h  2h  3h  4h 
Compound 
3a 
1/50  38,37±0,5
5 
38,03 ±0,3  36,43±0,4
5 
36,77±0,9  37,53±0,5  36,67±0,3
* 
1/100  38,1±0,89  36,83±0,6
1 
37.17±0,7
5 
37,37±0,6
5 
36.37±1,0
3 
37,5±1,04 
1/200  37,57 
±1,24 
36,8±1,22  36,85±0,7
8 
35,95±1,3
4 
36.55±0,9
2 
36,95±1,4
8 
Compound 
4c 
1/50  38,97 
±0,97 
36,73±1,2
4 
37,1±0,14  36,15±0,0
7 
37,45±0,4
9 
36,15±0,2
12* 
1/100  38,07 
±0,93 
37,4±0,4  37,47±0,0
6 
36,57±1,1
2 
37,53±0,3
1 
37±0,79 
1/200  38,27 
±0,58 
37,7±0,61  37,77±0,7  37,47±0,4
7 
37,47±0,8
1 
37,4±1,04 
paracetamol    38,03 
±0,76 
37,37±0,3  37,17±0,3  37,17±0,2
1 
36,9±0,95  37,83±0,2
1  *p ≤ 0.05:  vs control 
 
Evaluation of nociceptive activity  
The effect of two newly synthesized pyrozolopyrimidine derivatives (3a and 4c) on acetic 
induced  writhing  in  mice  was  given  in  Figure  2.    The  present  study  revealed  that  all 
compounds  showed  a  significant  nociceptive  effect  (P  <  0.001)  at  both  doses  (1/50  and 
1/100); they were able to reduced pain induced by acetic acid writhing responses in dose 
dependant manner as compared to positive control group (untreated group). Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  869 
 
 
 
Figure 2.  Nociceptive activity of certain pyrazolo[3,4-d]pyrimidines (3a) 
 
Evaluation of anti-inflammatory activity 
Inflammation is a complex reaction to injurious agents including microbes.  It involves 
vascular responses such as activation and migration of leukocytes and systemic reactions.  
The newly synthesized pyrozolopyrimidine derivatives were screened for anti-inflammatory 
activity using carrageenin induced rat hind paw edema method.  Anti-inflammatory activity of 
tested compounds and reference drug (ibuprofen) at different assessment times after injection 
are shown in Table 5.  
The  results  revealed  that  the  tested  compound  exhibited  anti-inflammatory  activity. 
Compound  3a  was  effective  in  the  inhibition  of  paw  edema  than  ibuprofen  during  all 
experimental periods.  After 2 hours, this activity was decreased in the order of compound                   
3a > ibuprofen. 
 
Table 5. Evaluation of anti-inflammatory activity 
 
Conclusion 
 
In conclusion, we have reported a simple and convenient approach to the synthesis of 
pyrazolo[3,4-d]pyrimidines by cyclization followed by Dimroth rearrangement of imidates 
derived from 5-amino-4-cyanopyrazoles in the presence of primary amines, hydrazines and 
hydroxylamine; while the condensation of imidates with some hydrazides derivatives gave the 
corresponding pyrazolo[4,3-d][1,2,4]triazolo[4,3-c]pyrimidines.  Further, the results obtained 
in this study indicate that these compounds possess potent anti-inflammatory, nociceptive and 
antipyretic properties, which are mediated via peripheral and central inhibitory mechanisms.  
 
paw edema (mm) 
dose  0h  2h  3h  4h 
Control  -----  2,15±0,21  7,41 ±0,28  7,41 ±0,28  8,01 ±0,18 
Compound 
3a 
22,2mg/kg PC  2,65±0,49  5,55 ±0,63  5,25±0,63  4,2±0,1* 
11 ,1mg/kgPC  2,75±0,63  5,95±0,37  6,25±0,91  5,85±0,65 
5,55mg/kg PC  2,57 ±1,24  5,8±0,22  6,85±0,68  6,85±0,14 
Ibuprofen  150mg/kg PC  2,05 ±0,76  6,25±1,3  5,14±0,9  4,19±0,72* Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  870 
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Experimental Section 
 
Chemistry 
General:  Commercially available reagent grade chemicals were used as received without 
additional purification.  All reactions were followed by TLC (E. Merck Kieselgel 60 F-254), 
Melting point were measured on an Electrothermal apparatus.  IR spectra were recorded on a 
Perkin-Elmer PARAGON FT-IR spectrometer. 
1H and 
13C NMR spectra were recorded on an 
AC Bruker spectrometer at 300 MHz (
1H) and 75 MHz (
13C) using (CD3)2SO and CDCl3 as 
solvents.    Chemical  shifts  (δ)  are  reported  in  parts  per  million  (ppm)  relative  to 
tetramethylsilane (0 ppm) as internal reference and the following multiplicity abbreviations 
were used: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; J (hertz).  The mass 
spectra were recorded on an ion trap mass spectrometer (Bruker Daltonics Data analysis 3.4). 
High resolution mass spectra (HRMS) were obtained on a Jeol GCmate spectrometer via 
direct introduction. 
 
General experimental procedure for the preparation of imidates (2a-e).              
The  required  pyrazole  (1.0  mmol)  was  treated  with  triethyl  orthoformate  or  triethyl 
orthoacetate (1.5 mmol) and few drops of acetic acid. The mixture was refluxed for 24h.  
After cooling, the product was filtered off and washed with ether. 
 
Ethyl N-4-cyano-1-phenyl-1H-pyrazol-5-ylformimidate 2a.  
White solid, yield:  70%, mp 56-57 °C. IR (cm
-1):  1596, 1625 (C=N), 2225 (CN). 
1H NMR: 
(300 MHz, DMSO-d6): δ (ppm) 1.26 (t, 3H), δ = 4.27 (q, 2H), δ = 7.35-7.61 (m, 6), 8.51      
(s,  1H). 
13C  NMR  (75  MHz,  DMSO-d6):  δ  (ppm)  C7  12.7,  C6  63.9,  C1 150.5,  C2  81.7, 
C3 150.5, C4 114.2, C5 162.1, Carom 123.2-137.5. 
Ethyl N-4-cyano-1-phenyl-1H-pyrazol-5-ylacetimidate 2b. 
White  solid,  yield:    62%,  mp  72-74°C.  IR(cm
-1):    1596,  1651  (C=N),  2229  (CN).                       
1H  NMR:  (300  MHz,  DMSO-d6):  δ  (ppm)  1.26  (t,  J
3  =  7,2  Hz,  3H),  2.49  (s,  3H),                 
4.27 (q, J
3 = 7.2 Hz,  2H), 7.35-7.61 (m, 5H), 8.51 (s, 1H). 
13C NMR (75 MHz, DMSO-d6):         
δ  (ppm)    C8  18.6,  C7  14.3,  C6  64.1,  C1 151.5,  C2  83.8,  C3 141.9,  C4 114.3,  C5 167.9,          
Carom 123.9-138.5. 
Ethyl N-4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-ylfomimidate 2c. 
White solid, yield:  70%, mp 105°C. IR(cm
-1):  1593, 1618 (C=N), 2214 (CN). 
1H NMR:  
(300 MHz, DMSO-d6):  δ (ppm) 1,47 (t, J
3 = 6.9 Hz, 3H), 2.30 (s, 3H), 4.27 (q, J
3 = 6.9 Hz, 
2H), 7.35-7.69 (m, 5H), 8.51 (s, 1H).
  13C NMR (75 MHz, DMSO-d6): δ (ppm) C7 13.2,                 
C8  14.3,  C6  64.4,  C2  82.3,  C4 114.7,  C3 151.01,  C1 151.0,  C5 162.6,  Carom  124.0-138.1.                
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Ethyl N-4cyano-3-methyl-1-phenyl-1H-pyrazol-5-ylacetimidate 2d 
Yield:  67%, IR (cm
-1): 1595, 1646 (C=N), 2220 (CN). 
1H NMR: (300 MHz, DMSO-d6):       
δ (ppm) 2.57 (s, 3H), 7.14 (t, 1H), 7.28 (t, 1H), 7.38 (t, 2H), 7.50 (t, 2H), 7.59 (d, 2H),                     
8.17 (d, 2H), 8.41 (s, 1H), 8.75 (s, 1H).
 13C NMR (75 MHz, DMSO-d6): δ (ppm) C6 15.2, 
C2 101.9, C1 142.8, C3 154.5, C5 156.0, C4 156.3, Carom 120.9-139.2.  
 
General experimental procedure for synthesis of pyrazolo[3,4-d]pyrimidin-4-amines   
(3a-f).  
A mixture of compound 2 (1 mmol) and primary amine or hydrazine (1 mmol) refluxed in 
toluene (10 ml) with acetic acid for 24h.  The separated product was filtered, washed with 
ether, dried and crystallized from ethanol to give compounds 3. 
 
3-methyl-N,1-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3a.  
White  solid,  yield:  67%,  mp  224°C.  IR  (cm
-1):  1563;  1580;  1609  (C=N),  3443  (NH).               
1H  NMR:    (300  MHz,  DMSO-d6):    δ  (ppm)  2.57  (s,  3H),  7.14  (t,  1H),  7.28  (t,  1H),                    
7.38 (t, 2H), 7.50 (t, 2H), 7.59 (d, 2H), 8.17 (d, 2H), 8.41 (s, 1H), 8.75 (s, 1H).
 13C NMR               
(75 MHz, DMSO-d6): δ (ppm) C6 15.2, C2 101.9, C1 142.8, C3 154.5, C5 156.0, C4 156.3, 
Carom 120.9-139.2. HRMS calculated for C18H15N5: 301.1327; found: 301.1328. 
3,6-dimethyl-N,1-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3b.  
White solid,  yield:   63%, mp  177°C. IR (cm
-1):  1560;  1581; 1616   (C=N),  3446 (NH).               
1H  NMR:  (300  MHz,  DMSO-d6):    δ  (ppm)  2.47  (s,  3H);  2.70  (s,  3H);  7.11  (t,  1H);                 
7.27  (t,  1H);  7.37-8.18  (m,  8H);  8.59  (s,  1H).
  13C  NMR  (75  MHz,  DMSO-d6):  δ  (ppm)                        
C6  15.2,  C7  26.7,  C2 100.10,  C1 142.8,  C3 154.3,  C5 156.8,  C4 157.5,  Carom  120.9-140.1. 
HRMS calculated for C19H17N5: 315.1484; found:  315.1482. 
N-benzyl-3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3c.  
White solid, yield:  77%, mp 125°C. IR (cm
-1):  1567; 1590 (C=N), 3440 (NH). 
1H NMR: 
(300 MHz, DMSO-d6): δ (ppm) 2.68 (s, 3H), 4.23 (d, J
2 = 6 Hz, 1H), 4.78 (d, J
2 = 6 Hz, 1H), 
7.22 (m, 1H), 7.27 (t, 2H), 7.35 (d, 2H), 7.49 (t, 2H), 7.92 (t, 2H), 8.15 (d, 2H), 8.31 (s, 1H). 
13C NMR (75 MHz, DMSO-d6): δ (ppm) C6 15.2, C7 43.8, C2 101.1, C1 142.8, C3 154.3, 
C5 156.4,  C4 157.5,  Carom  120.1-140.8.  HRMS  calculated  for  C19H17N5:  315.1484;                     
found: 315.1485. 
N-benzyl-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3d.  
White  solid,  yield:    68%,  mp  119°C.  IR  (cm
-1):   1509,  1570,  1586  (C=N),  3450  (NH).            
1H  NMR:  (300  MHz,  DMSO-d6):  δ  (ppm)  2.68  (s,  3H),  4.23  (d,  J  =  6  Hz,  1H),                   
4.78 (d, J = 6 Hz, 1H), 7.22 (m, 1H), 7.27 (t, 2H), 7.35 (d, 2H), 7.49 (t, 2H), 7.92 (t, 2H),  
8.15  (d,  2H),  8.31  (s,  1H). 
13C  NMR  (75  MHz,  DMSO-d6):  δ  (ppm)  C6  15.2,  C7  43.8, 
C2 101.1, C1 142.8,  C3 154.3, C5 156.4, C4 157.5, Carom 120.1-140.8. MS m/z:  316. 
3-methyl-N-(naphtalen-2-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3e.  
Broun solid, yield: 80%, mp 209°C. IR (cm
-1): 1560, 1589 (C=N), 3386 (NH). 
1H NMR:  
(300 MHz, DMSO-d6): δ (ppm)  2.77 (s, 3H), 7.28-8.21(m, 13H), 9.28 (s, 1H). 
13C NMR    
(75 MHz, DMSO-d6): δ (ppm) C6 15.4, C2 101.6, C1 143.1, C3 154.7, C5 156.6, C4 157.8, 
Carom 121.0-139.3. HRMS calculated for C22H17N5: 351.1484; found: 351.1486. 
3,6-dimethyl-N-(naphtalen-2-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 3f.  
Broun solid, yield:  48%, mp 208°C. IR (cm
-1):  1562, 1588 (C=N), 3415 (NH). 
1H NMR: 
(300 MHz, DMSO-d6):  δ (ppm)  2.28 (s, 3H), 2.62 (s, 3H), 7.28-8.20 (m, 11H), 9.15 (s, 1H). Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  872 
 
 
13C NMR (75 MHz, DMSO-d6):  δ (ppm) C6 15.4, C7 26.6, C1 132.9, C2 99.8, C3 155.9, 
C4 165.8, C5 157.4, Carom 120.9-139.4. 
 
General experimental procedure for synthesis of pyrazolo[3,4-d]pyrimidin- 
4-hydrazines (4a-d).  
A mixture of hydrazine (1 mmol) and imidate 2 (1 mmol) was heated at reflux for 24 h in 
toluene  (10mL)  with  acetic  acid.  The  product,  which  precipitates,  was  filtered  and 
recrystallized from ethanol. 
 
1-(3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)hydrazine 4a.  
Yellow solid, yield:  37%, mp 231°C. IR (cm
-1): 1488, 1560, 1581 (C=N), 3268, 3312 (NH). 
1H  NMR:  (300  MHz,  DMSO-d6):  δ  (ppm)  2.60  (s,  3H),  4.75  (s,  2H),  7.62  (t,  1H),               
7.48 (t, 2H), 8.13 (d, 2H), 8.34 (s, 1H), 8.80 (s, 1H). 
13C NMR (75 MHz, DMSO-d6):  δ (ppm) 
C6 14.9, C1 142.7, C2 99.3, C3 153.5, C4 158.0, C5 157.5, Carom 120.3-142.2. MS m/z:  241. 
1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)hydrazine 4b.  
Yellow  solid,  yield:    52%,  IR  (cm
-1):  1599,  1650,  1698  (C=N),  3036,  3194  (NH).                           
1H  NMR:  (300  MHz,  DMSO-d6):    δ  (ppm)  2.44  (s,  3H),  2.59  (s,  3H),  5.67  (s,  2H),                   
7.30 (t, 1H), 7.49 (t, 2H), 7.16 (d, 2H), 8.99 (s, 1H). 
4-methyl-N’-(3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) benzene-
sulfonohydrazide 4c.  
White solid, yield:  84%, mp 268°C. IR (cm
-1):  1488, 1560, 1581 (C=N), 3268, 3312 (NH). 
1H  NMR:  (300  MHz,  DMSO-d6):    δ  (ppm)  2.60  (s,  3H),  4.75  (s,  2H),  7.62  (t,  1H),               
7.48 (t, 2H), 8.13 (d, 2H), 8.34 (s, 1H), 8.80 (s, 1H). 
13C NMR (75 MHz, DMSO-d6): δ (ppm) 
C6 14.9, C1 142.7, C2 99.3, C3 153.5, C4 158.0, C5 157.5, Carom 120.3-142.2. MS m/z:  241. 
4-methyl-N’-(3,4-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) benzene-
sulfonohydrazide 4d.  
White solid, yield:  36%, mp 212°C. IR (cm
-1):  1559, 1593, 1655 (C=N), 3217, 3367 (NH). 
1H NMR: (300 MHz, DMSO-d6): δ (ppm) 2.39 (s, 3H), 2.45 (s, 3H), 2.69 (s, 3H),  7.23-7.51 
(m, 9H), 7.72 (s, 1H), 8.00 (s, 1H).
 13C NMR (75 MHz, DMSO-d6):  δ (ppm) C6 14.4, C7 23.0, 
C8 21.5, C1 142.4, C2 99.9, C3 144.4, C4 161.8, C5 154.2, Carom 121.9-140.3. 
 
General experimental procedure for synthesis of 4-amino-pyrazolo[3,4-d] pyrimidine 
(5a-c).  
A  solution  of  imidate  2  (1.0  mmol)  in  ethanol  (5mL)  was  treated  with  ammoniac                          
(2.0 mmol) and a catalytic amount of acetic acid.  The reaction mixture was refluxed for 6h, 
and the formed solid was collected by filtration, dried and recrystallized from ethanol to give 
compound 5.  
 
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine  5a.  
White  solid,  yield 83  %  ;  mp    228  °C;  IR(cm
-1):    3283  (NH2),  1480, 1500,  1590(C=N).                
1H  NMR:  (300  MHz,  DMSO-d6):    δ  (ppm)  4.69  (s,2H),  7.36  (t,  J  =  7.3Hz,  1H),                            
7.48 ( t, J = 7.3Hz, 2H), 7.52 (d, J = 7.3Hz, 2H), 7.60 ( s,1H), 7.72 (s,1H). 
13C RMN (75 
MHz,  DMSO-d6):  δ  (ppm)114.1,  124.2,  129.0,  129.5,  130.0,  136.9,  141.3,  149.8,  156.8; 
HRMS calculated for C11H9N5: 211.0858, found:  211.0859. Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  873 
 
 
3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 5b.  
Yield 68  %;  mp  192  °C;  IR(cm
-1)    3317(NH2),  1626,  1647,  1665(C=N).    RMN 
1H                 
(δ ppm, DMSO-d6):  2.76 (s, 3H), 5.97 (s, 2H), 7.33(t, J = 7.1Hz, 1H) , 7.57(t, J = 7.1Hz, 
2H),  8.16  (d,  J  =  7.1Hz,  2H),    8.46  (s,  1H); 
13C  NMR  (75  MHz,  DMSO-d6):  δ  (ppm) 
14.8, 101.2, 121.4, 126.3, 129.1, 138.8, 141.8, 154.4, 156.4,   158.4. HRMS  calculated for 
C12H11N5:  225.1014, found:  225.1018. 
6-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine  5c.  
Yield 70 % ; mp 160 °C; IR(cm
-1) 3320(NH2),1597, 1638, 1663(C=N). RMN 
1H (δ ppm, 
DMSO-d6):  2.65  (s,  3H),  4.28  (s,2H),  7.28(t,  J  =  7.3Hz,  1H),  7.56  (t,  J  =  7.3Hz,  2H),          
8.19(d, J = 7.3Hz, 2H), 8.29 (s, 1H); 
13C NMR (75 MHz, DMSO-d6): δ (ppm) 14.4, 100.2, 
Carom  120.2,  124.6,  129.1,  138.8,   142.7,  C3 154.1, 156.5, 158.5.  HRMS  calculated  for 
C12H11N5:  225.1014, found:  225.1016. 
 
General experimental procedure for synthesis of N-hydroxy-pyrazolo                            
[3,4-d]pyrimidin-4-amines (6a-b).  
A mixture of imidate 2 (1 mmol) and hydroxylamine hydrochloride (1 mmol) in ethanol 
was heated for 24 h with triethylamine (1 mmol).  The solvent was then removed and the 
residue was extracted with dichloromethane (3×50 ml).  Collected organic layers were dried 
over MgSO4, and then the solvent was evaporated.  
 
N-hydroxy-3-methyl-1-phenyl-1H- pyrazolo[3,4-d]pyrimidin-4-amine 6a.  
White solid, yield:  36%, mp 265°C. IR (cm
-1): 1561, 1593, 1650   (C=N), 3286 (OH), 3405 
(NH). 
1H NMR: (300 MHz, DMSO-d6):  δ (ppm) 2.65 (s, 3H), 7.30 (t, 1H), 7.50 (t, 2H), 8.04 
(d,  2H),  8.49  (s,  2H),  8.72  (s,  1H).
13C  NMR  (75  MHz,  DMSO-d6):    δ  (ppm)  C6  14.6, 
C1 142.8, C2 100.7, C3 146.4, C4 149.3, C5 146.3, Carom 120.7-138.6. HRMS calculated for 
C12H11N5O: 241.0964; found:  241.0956. 
N-hydroxy-3,6-dimethyl-1-phenyl-1H- pyrazolo[3,4-d]pyrimidin-4-amine 6b. 
White  solid,  yield:  32%,  mp  240°C.  IR  (cm
-1):  1573,  1594,  1654  (C=N),  2971  (OH),               
3262 (NH).
1H NMR: (300 MHz, DMSO-d6):  δ (ppm) 2.74 (s, 3H), 2.83 (s, 3H), 7.30-7.56 
(m, 5H), 7.98 (s, 1H), 8.04 (s, 1H). 
13C NMR (75 MHz, DMSO-d6): δ (ppm) C6 15.3, C7 21.2, 
C1 142.8, C2 101.6, C3 148.8, C4 156.4, C5 157.1, Carom 121.1-138.2.  HRMS calculated for 
C13H13N5O: 255.1120; found:  255.1112. 
 
General  experimental  procedure  for  synthesis  of  pyrazolo[3,4-d][1,2,4]triazolo              
[4,3-c]pyrimidines (7a-d).  
A mixture of hydrazide (1 mmol) and imidate 2 (1 mmol) was heated at reflux for 24 h in 
toluene  (10mL)  with  acetic  acid.    The  product,  which  precipitates,  was  filtered  and 
recrystallized from ethanol. 
 
7a:    White  solid,  yield:    79%,  mp  232°C.  IR  (cm
-1):    1538,  1590,  1652    (C=N).                              
1H NMR:  (300 MHz, DMSO-d6): δ (ppm) 2.81 (s, 3H), 7.39-8.28 (m, 10H), 9.61 (s, 1H).             
13C NMR (75 MHz, DMSO-d6):  δ (ppm) C7 15.1, C2 101.6, C1 138.8, C3 142.4, C4 145.5, 
C5 149.6,  C6 164.2,  Carom  121.7-136.7.    HRMS  calculated  for  C19H14N6:    326.1280; 
found:326.1280. 
7b:    White  solid,  yield:    52%,  mp  241°C.  IR  (cm
-1):    1504,  1540,  1591,  1658    (C=N).                  
1H NMR:  (300 MHz, DMSO-d6):  δ (ppm) 1.90 (s, 3H), 2.36 (s, 3H), 7.49-7.92 (m, 10H), Mediterr.J.Chem., 2014, 3(2),  A. Agrebi et al.  874 
 
 
10.52 (s, 1H). 
13C NMR (75 MHz, DMSO-d6):  δ (ppm) C7 13.3, C8 15.6, C2 100.8, C1 138.9, 
C3 142.6, C4 145.3, C5 149.5, C6 164.2, Carom122.0-137.6.  HRMS calculated for C20H16N6: 
340.1436; found:  340.1434. 
7c:  White solid, yield:  48%, mp 201°C. IR (cm
-1):  1497, 1544, 1595, 1650  (C=N). 
1H 
NMR:    (300  MHz,  DMSO-d6):  δ  (ppm)  2.48  (s,  3H),  2.72  (s,3H),  7.39  (t,  1H),                         
7.57-8.10(m, 4H), 9.45 (s, 1H). 
13C NMR (75 MHz, DMSO-d6):  δ (ppm) C7 13.4, C8 14.1, 
C1 139.9,  C2 100.5,  C3 142.4,  C4 164.7,  C5 146.1,  C6 167.8,  Carom126.9-138.0.                              
HRMS calculated for C14H12N6: 264.1123; found:  264.1124. 
7d:   White solid,  yield:    52%,  mp  130 °C.  IR (cm
-1):   1544, 1599, 1650, 1698   (C=N).          
1H  NMR:  (300  MHz,  DMSO-d6):    δ  (ppm)    2.58  (s,  3H),  2.80  (s,  3H),  3.34  (s,  3H),                   
7.36 (t, 1H), 7.54 (t, 2H), 8.07 (d, 2H).
13C NMR (75 MHz, DMSO-d6):  δ (ppm) C7 13.8,               
C8 14.7, C9 20.7, C2 101.6, C1 138.8, C3 142.6, C4 145.3, C5 149.6, C6 164.2, Carom 121.7-
136.8. 
 
Biological evaluation 
Laboratory bred Wister rats (120-220 g) and Swiss mice (20-35 g) of either sex, purchased 
from  Central  Pharmacy  (SIPHAT,  Tunisia),  were  used  for  the  in-vivo  pharmacological 
testing.    All  experiments  were  conducted  in  accordance  with  the  internationally  accepted 
principals for laboratory animal use.  All animals were maintained under standard laboratory 
conditions at 22 ±2°C, with relative humidity 50 ± 15% and photoperiod (12h light and dark 
cycle).  Commercial pellet diet and water were provided ad libitum.  The animals were fasted 
overnight prior to each experiment. 
 
Acute toxicity study 
Acute toxicity studies were performed on Swiss mice either sex selected randomly.  Six 
single doses (2366, 1183, 473, 236, 47, 23 mg/kg) of 3-methyl-N,1-diphenyl-1H-pyrazolo 
[3,4-d]pyrimidin-4-amine 3a  and  4-methyl-N’-(3-methyl-1-phenyl-1H-pyrazolo[3,4-d] 
pyrimidin-4-yl)benzenesulfonohydrazide  4c  were  administrated  intraperitoneally  (i.p.)  to 
different groups containing ten mice each.  Mice were kept under regular observation for 48h 
for any adverse effect, including mortality.  Other behavioural changes and parameters, such 
as  body  weight,  food intake, urination,  water intake, locomotor activity, changes  in  skin, 
respiration,  tremors,  temperature,  etc.,  were  also  observed.    None  of  the  treated  groups 
displayed any significant change of behaviour as compared with the untreated controls. 
 
Acetic acid induced writhing test 
The peripheral anti-nociceptive activity of pyrazolo[3,4-d]pyrimidines was evaluated by 
acetic acid induced writhing test
16.  Adult Wister rats of either sex were randomized into five 
groups  of  six  mice  each.    Pyrazolo[3,4-d]pyrimidines  (50  mg/Kg,  i.p.)  and  aspirine                  
(150 mg / kg, i.p.) were administered to respective group of rats.  After 30 min, 1% aqueous 
solution of acetic acid (10 ml / kg) was administrated i.p. to induce pain sensation.  Writhing 
movement was recognized as contraction of abdominal muscle together with stretching of 
hind limbs.  The number of writhing movements for each mouse was counted for 20 min after 
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Carrageenin-induced paw oedema in rats 
Pedal inflammation was produced according to the method described by Winter et al
17.  In 
this study 0.1 mL of 1% carrageenin was injected into the right hind foot paw of each rat 
under the subplanter aponeurosis.  Animal grouping and dosage administration were as in the 
plate test.  Animals were administrated intraperitoneally the product 1h before carrageenan 
injection.  Measurement of paw size was carried out as in previous studies
18 by wrapping a 
piece of cotton thread round the paw and the length of the thread corresponding to the paw 
circumference was determined using a meter ruler. 
Paw size were measured immediately before and 1-5h following injection.  The inhibitor 
activity was determined as follows.
 18  
 
Percentage inhibition =   
 
Where Ct = paw circumference at time t, C0 = paw circumference before carrageenan 
injection and Ct-C0 = oedema. 
 
Brewer’s yeast induced pyrexia 
The antipyretic activity of pyrazolo[3,4-d]pyrimidines was assisted by the yeast induces 
pyrexia  method  as  described  previously
19  with  little  modification.    Adult  rats  were 
randomized into five different groups of six rats each.  
The rectal temperature of each rat was measured 17h (normal control) after brewer’s yeast 
injection using a clinical thermometer.  Only rats that showed an increase in temperature of at 
least  0.7°C  were  used  for  this  study.    Animals  were  administrated  (orally)  the  pyrazolo                  
[3,4-d]pyrimidine 18h after the brewer’s yeast injection and rectal temperature were measured 
at 60, 90 and 120 min post administration.  The mean of the rectal temperature of each group 
were determined and compared with pre-drug (hyperpyretic state) temperature. 
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